8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    Form 8-K


                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): July 13, 2004

                          Savient Pharmaceuticals, Inc.
               (Exact name of issuer as specified in its charter)




               Delaware                 0-15313                13-3033811
       (State or Other Jurisdiction (Commission File Number)   (IRS Employer
            of Incorporation)                                Identification No.)


                One Tower Center, 14th Floor
                East Brunswick, New Jersey                 08816
               (Address of Principal Executive Offices) (Zip Code)


       Registrant's telephone number, including area code: (732) 418-9300


                                      None.
         (Former Name or Former Address, if Changed Since Last Report.)










Item 7.  Financial Statements and Exhibits

(c)  Exhibits

      Exhibit 99.1           Description
                             Press Release dated July 13, 2004 (filed herewith).




ITEM 9.  REGULATION FD DISCLOSURE.

                  On July 13, 2004, Savient Pharmaceuticals, Inc. issued a press
release announcing the election, at its Annual Meeting of Shareholders, of
Christopher Clement, the Company's President & Chief Executive Officer to its
Board of Directors and the reelection of all nine current members of the Board
of Directors to serve for an additional one-year term. Mr. Clement was also
appointed to the position of Acting Chairman, pending the completion of
recommendations from the Company's Nominating and Corporate Governance Committee
of the Board as to a permanent Chairperson. In addition, the Company also
announced the approval by its stockholders of the Savient Pharmaceuticals, Inc.
2004 Incentive Plan, which does not increase the total number of Savient shares
of common stock previously approved by the Company's stockholders for issuance
under the 2001 Plan but amends, restates, and consolidates the Company's 2001
Stock Option Plan and the Stock Compensation Plan for Outside Directors to
provide the Company the ability to make additional forms of short and long term
equity-based incentive compensation awards to its employees that were not
permitted under the 2001 Plan and to make automatic awards of shares of the
Company's common stock and options to its non-employee directors, while
controlling the dilutive effects to existing shareholders. A copy of the press
release is attached as Exhibit 99.1.

                  The information furnished pursuant to Item 9 in this Form 8-K
shall not be deemed to be "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
Section, unless we specifically incorporate it by reference in a document filed
under the Securities Act of 1933 or the Securities Exchange Act of 1934. We
undertake no duty or obligation to publicly update or revise the information
furnished pursuant to Item 9 in this Form 8-K.











                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                  SAVIENT PHARMACEUTICALS, INC.
                                  (Registrant)


                                   By: /S/ PHILIP K.  Yachmetz
                                       -------------------------------------
                                       Philip K. Yachmetz
                                       Senior Vice President, General Counsel
                                       and Secretary



Dated: July 15, 2004

EX-99.1

                                                                    Exhibit 99.1

Savient Pharmaceuticals, Inc. Announces Results of Annual Meeting of
Stockholders; Christopher Clement Assumes CEO Post and Joins Board of
Directors

    EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--July 13, 2004--At its
annual meeting of stockholders yesterday, Savient Pharmaceuticals,
Inc. (NASDAQ:SVNT) announced the election of Christopher Clement to
the Company's Board of Directors. Stockholders also re-elected all
other members of the Board: Herbert J. Conrad, President (retired),
Roche Pharmaceuticals Division, Hoffmann La-Roche, Ltd.; Sim Fass,
(who retired as Chairman and Chief Executive Officer of the Company
effective at the adjournment of the Annual Meeting); Jeremy
Hayward-Surry, President (retired), Pall Corporation; Stephen O.
Jaeger, Chairman, Chief Executive Officer, President, eBT
International, Inc; Carl E. Kaplan, Esq., Senior Partner, Fulbright &
Jaworski LLP; David Tendler, Partner, Tendler Beretz LLC; Virgil
Thompson, President and Chief Executive Officer, Angstrom
Pharmaceuticals, Inc.; Faye Wattleton, President, Center for the
Advancement of Women; and Herbert Weissbach, Ph.D., Distinguished
Research Professor, Director, Center for Molecular Biology and
Biotechnology, Florida Atlantic University. All Directors were elected
for a one-year term.
    Stockholders also approved the Savient Pharmaceuticals, Inc. 2004
Incentive Plan, which amends, restates, and consolidates the Company's
2001 Stock Option Plan and Stock Compensation Plan for Outside
Directors. The 2004 Incentive Plan enables us to remain competitive
with current compensation trends by allowing us to make additional
types of equity-based compensation awards to our employees that are
not permitted under the 2001 Plan and to make automatic awards of
shares of our common stock and options to our non-employee directors.
These additional forms of equity-based compensation will increase our
ability to create effective short and long term incentive programs for
our employees while controlling the dilutive effects to our existing
shareholders. This plan, which does not increase the total number of
our shares of common stock previously approved by our shareholders for
issuance under the 2001 Plan, will also allow us to provide long-term
incentive compensation that is more in line with developing trends,
particularly in light of the anticipated requirement to expense stock
options.
    Effective at the close of the annual meeting and as previously
announced, Sim Fass retired as Chairman and Chief Executive Officer of
Savient, and Christopher Clement, who joined the Company in May 2002
as President and Chief Operating Officer, succeeded him as Chief
Executive Officer. Mr. Clement now serves as President and CEO. He was
also appointed to the position of Acting Chairman, pending the
completion of recommendations from the Nominating and Corporate
Governance Committee of the Board as to a permanent Chairperson.
    At the annual meeting, Mr. Clement announced that Savient and its
Board are engaged in a comprehensive review of Savient's business
operations and strategic plan in order to refine its focus to maximize
the Company's assets and shareholder value.
    "I look forward to working closely with our staff and the Board of
Directors as we refine our focus and determine how best to realize the
promise and opportunities represented by our portfolio of products and
exciting drug candidates in clinical development," said Mr. Clement.
"In the coming weeks and months, we expect to communicate to our
stockholders the decisions and actions that will stem from our current
strategic review."

    About Savient Pharmaceuticals, Inc.

    Savient Pharmaceuticals, Inc. is engaged in developing,
manufacturing, and marketing pharmaceutical products that address
unmet medical needs in both niche and wider markets. Products marketed
by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and
Delatestryl(R) (testosterone enanthate). The Company's subsidiary,
Rosemont Pharmaceuticals Limited, develops, manufactures, and markets
through its own sales force oral liquid formulations of prescription
products for the UK pharmaceutical market. The Company's Israeli
subsidiary, Bio-Technology General (Israel) Ltd., manufactures and
markets in Israel Bio-Tropin(TM) (recombinant human growth hormone),
BioLon(R) (sodium hyaluronate), Bio-Hep-B(R) (hepatitis B vaccine),
and Arthrease(TM) (sodium hyaluronate for osteoarthritis). Products
marketed by Savient's licensees are Mircette(R) (oral contraceptive),
and BioLon(R) in the United States, and Bio-Tropin(TM), BioLon(R),
Bio-Hep-B(R), Silkis(R) (vitamin D derivative), and recombinant human
insulin, in international markets. Savient's news releases and other
information are available on the Company's website at
www.savientpharma.com.

    Arthrease is a trademark of DePuy Orthopaedics, Inc., except in
Israel, where it is owned by Bio-Technology General (Israel) Ltd.,
Savient's wholly owned subsidiary; Mircette is a registered trademark
of Organon, Inc.; Silkis is a registered trademark of Galderma S.A.

    Statements in this news release concerning the Company's business
outlook or future economic performance, anticipated profitability,
revenues, expenses or other financial items; and statements concerning
assumptions made or expectations as to any future events, conditions,
performance or other matters, are "forward-looking statements" as that
term is defined under the Federal Securities Laws. Forward-looking
statements are subject to risks, uncertainties and other factors that
could cause actual results to differ materially from those stated in
such statements. Such risks, uncertainties and factors include, but
are not limited to, the timing of the introduction of a generic
version of Oxandrin, changes and delays in product development plans
and schedules, changes and delays in product approval and
introduction, customer acceptance of new products, development,
introduction, or consumer acceptance of competing products, changes in
pricing or other actions by competitors, patents owned or licensed by
the Company and its competitors, changes in healthcare reimbursement,
risk of operations in Israel, risk of product or other litigation
liability, governmental regulation, dependence on third parties to
manufacture products and commercialize products, and general economic
conditions, as well as other risks detailed in the Company's filings
with the Securities and Exchange Commission.

    CONTACT: Investor Relations:
             Wolfe Axelrod Weinberger Assoc.
             Don Weinberger, 212-370-4500
              or
             Savient Pharmaceuticals, Inc.
             Leah Berkovits, 732-418-9300